PEAK
Healthpeak Properties, Inc. [PEAK] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
PEAK Stock Summary
Top 10 Correlated ETFs
PEAK
Top 10 Correlated Stocks
PEAK
In the News
March Madness for REITs? Here's a ‘final four' for investors seeking dividend income.
“Final four” is an eye-popping term, and will signal maximum excitement for fans of the NCAA Men's Division 1 Basketball Tournament, when we see which teams win games among the “elite eight” on March 26.
Why Is Healthpeak (PEAK) Down 12% Since Last Earnings Report?
Healthpeak (PEAK) reported earnings 30 days ago. What's next for the stock?
Is It Time To Sell This Healthcare Stock?
After some questionable moves in recent years, should investors move on?
Healthpeak Properties: A Solid End To 2022 And A Positive Future Outlook
Healthpeak Properties is an owner and operator of healthcare properties across the U.S. and is a REIT and S&P 500 component. Similar to other healthcare-related REITs, PEAK has and is likely to continue benefitting from favorable long-term demand drivers, such as an aging senior population.
Healthpeak Properties, Inc. (PEAK) Q4 2022 Earnings Call Transcript
Healthpeak Properties, Inc. (NYSE:PEAK ) Q4 2022 Results Conference Call February 8, 2023 11:00 AM ET Company Participants Andrew Johns - Senior Vice President, IR Scott Brinker - CEO, President & Director Scott Bohn - Chief Development Officer & Co-Head, Life Science Peter Scott - CFO Thomas Klaritch - COO Conference Call Participants Nicholas Yulico - Scotiabank Austin Wurschmidt - KeyBanc Capital Markets Juan Sanabria - BMO Capital Markets Steve Sakwa - Evercore ISI Vikram Malhotra - Mizuho Richard Anderson - SMBC Ronald Kamden - Morgan Stanley Michael Griffin - Citi Joshua Dennerlein - Bank of America Merrill Lynch Steven Valiquette - Barclays Bank Omotayo Okusanya - Credit Suisse John Pawlowski - Green Street Advisors Daniel Hogan - Baird & Co. Operator Good morning, and welcome to the Healthpeak Properties, Inc. Fourth Quarter Conference Call. All participants will be in listen-only mode [Operator Instructions].
Healthpeak's (PEAK) FFO and Revenues Surpass Estimates in Q4
Healthpeak's (PEAK) Q4 results outshine estimates on better-than-anticipated revenues. Same-store net operating income for the total portfolio improves year over year.
Healthpeak (PEAK) Q4 FFO and Revenues Top Estimates
Healthpeak (PEAK) delivered FFO and revenue surprises of 2.33% and 0.87%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Healthpeak (PEAK) This Earnings Season?
High demand for Healthpeak's (PEAK) life-science assets and rising healthcare spending by senior citizens are likely to have aided its Q4 earnings. Interest rate hikes might have been a deterrent.
7 REITs That Will Be Big Winners in 2023
Last year was the worst year for publicly-traded real estate investment trusts, or REITs, since 2008, as was recently pointed out in an article on WealthManagement . The FTSE All Equity REIT Index lost a quarter of its value last year compared with a 40% drop during 2008.
8 Real Estate Stocks That Could Crush the Market
I own all eight and think they could be major long-term outperformers.
PEAK Financial details
PEAK Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 3.92 | 4.11 | 3.1 | 3.57 | 3.83 | |
| Net income per share | 2.26 | 0.09 | 0.78 | 0.95 | 0.96 | |
| Operating cash flow per share | 1.8 | 1.74 | 1.43 | 1.5 | 1.67 | |
| Free cash flow per share | 1.8 | 1.74 | 1.43 | 1.5 | 1.47 | |
| Cash per share | 0.24 | 0.3 | 0.08 | 0.38 | 1.45 | |
| Book value per share | 12.63 | 12.51 | 12.79 | 12.28 | 12.35 | |
| Tangible book value per share | 13.19 | 13.03 | 12.86 | 12.49 | 12.75 | |
| Share holders equity per share | 12.63 | 12.51 | 12.79 | 12.28 | 12.35 | |
| Interest debt per share | 12.57 | 13.72 | 12.62 | 12.31 | 0.32 | |
| Market cap | 13.14B | 16.76B | 16.04B | 19.15B | 13.51B | |
| Enterprise value | 18.68B | 23.06B | 22.47B | 25.36B | 13.44B | |
| P/E ratio | 12.39 | 368.14 | 38.78 | 37.88 | 26.16 | |
| Price to sales ratio | 7.12 | 8.39 | 9.75 | 10.1 | 6.55 | |
| POCF ratio | 15.49 | 19.81 | 21.15 | 24.08 | 15 | |
| PFCF ratio | 15.49 | 19.81 | 21.15 | 24.08 | 17.06 | |
| P/B Ratio | 2.21 | 2.75 | 2.36 | 2.94 | 2.03 | |
| PTB ratio | 2.21 | 2.75 | 2.36 | 2.94 | 2.03 | |
| EV to sales | 10.12 | 11.55 | 13.66 | 13.38 | 6.52 | |
| Enterprise value over EBITDA | 10.05 | 25.23 | 17.03 | 18.86 | 9.57 | |
| EV to operating cash flow | 22.01 | 27.26 | 29.63 | 31.89 | 14.92 | |
| EV to free cash flow | 22.01 | 27.26 | 29.63 | 31.89 | 16.97 | |
| Earnings yield | 0.08 | 0 | 0.03 | 0.03 | 0.04 | |
| Free cash flow yield | 0.06 | 0.05 | 0.05 | 0.04 | 0.06 | |
| Debt to equity | 1.04 | 1.21 | 1.26 | 1.24 | 1.27 | |
| Debt to assets | 0.49 | 0.52 | 0.54 | 0.53 | 0.54 | |
| Net debt to EBITDA | 2.98 | 6.89 | 4.88 | 4.62 | -0.05 | |
| Current ratio | 0.91 | 1.91 | 2.27 | 0.37 | 1.37 | |
| Interest coverage | 1.86 | 1.62 | 0.99 | 2.15 | 2.97 | |
| Income quality | 0.8 | 18.58 | 1.83 | 1.57 | 1.74 | |
| Dividend Yield | 0.05 | 0.04 | 0.05 | 0.03 | 0.05 | |
| Payout ratio | 0.66 | 15.82 | 1.9 | 1.29 | 1.25 | |
| Sales general and administrative to revenue | 0.05 | 0.05 | 0.06 | 0.05 | 0.06 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.02 | 0.02 | 0.03 | 0.03 | 0.03 | |
| Capex to operating cash flow | 0 | 0 | 0 | -0.14 | -0.12 | |
| Capex to revenue | 0 | 0 | 0 | -0.06 | -0.05 | |
| Capex to depreciation | 0 | 0 | 0 | -0.16 | -0.15 | |
| Stock based compensation to revenue | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Graham number | 25.32 | 5.13 | 14.98 | 16.23 | 16.32 | |
| ROIC | 0.04 | 0.04 | 0.01 | 0.02 | 0.03 | |
| Return on tangible assets | 0.09 | 0 | 0.03 | 0.03 | 0.03 | |
| Graham Net | -12.78 | -14.47 | -15.74 | -14.25 | -13.78 | |
| Working capital | -33.61M | 446.53M | 1.67B | -1.22B | 309.47M | |
| Tangible asset value | 6.21B | 6.34B | 6.82B | 6.63B | 6.87B | |
| Net current asset value | -5.85B | -6.43B | -5.6B | -7.4B | -7.33B | |
| Invested capital | 0.95 | 1.06 | 0.95 | 0.98 | 0 | |
| Average receivables | 232.61M | 180.58M | 243.82M | 351.07M | 419.67M | |
| Average payables | 0 | 0 | 0 | 113.82M | 113.82M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 21.97 | 45.68 | 52.73 | 89.41 | 66.38 | |
| Days payables outstanding | 0 | 0 | 0 | 107.45 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 16.61 | 7.99 | 6.92 | 4.08 | 5.5 | |
| Payables turnover | 0 | 0 | 0 | 3.4 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 0.18 | 0.01 | 0.06 | 0.08 | 0.08 | |
| Capex per share | 0 | 0 | 0 | -0.21 | -0.2 |
Quarterly Fundamentals Overview
Last date of statement is 2022-12-31 for Q4
| Metric | History | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 0.9 | 0.92 | 0.96 | 0.97 | 0.97 | |
| Net income per share | 0.05 | 0.13 | 0.13 | 0.66 | 0.04 | |
| Operating cash flow per share | 0.42 | 0.36 | 0.47 | 0.45 | 0.38 | |
| Free cash flow per share | 0.42 | 0.36 | 0.47 | 0.45 | 0.18 | |
| Cash per share | 0.38 | 0.17 | 0.88 | 0.21 | 1.45 | |
| Book value per share | 12.09 | 11.88 | 11.69 | 12.01 | 12.35 | |
| Tangible book value per share | 12.29 | 12.14 | 12.02 | 12.41 | 12.75 | |
| Share holders equity per share | 12.09 | 11.88 | 11.69 | 12.01 | 12.35 | |
| Interest debt per share | 11.89 | 12.19 | 12.41 | 12.7 | 0.09 | |
| Market cap | 19.46B | 18.52B | 13.98B | 12.34B | 13.51B | |
| Enterprise value | 25.67B | 24.97B | 20.56B | 19.02B | 13.44B | |
| P/E ratio | 169.11 | 64.64 | 51.14 | 8.72 | 150.07 | |
| Price to sales ratio | 40.26 | 37.15 | 26.99 | 23.71 | 25.76 | |
| POCF ratio | 86.89 | 95.35 | 54.72 | 50.65 | 65.27 | |
| PFCF ratio | 86.89 | 95.35 | 54.72 | 50.65 | 137.21 | |
| P/B Ratio | 2.99 | 2.89 | 2.22 | 1.91 | 2.03 | |
| PTB ratio | 2.99 | 2.89 | 2.22 | 1.91 | 2.03 | |
| EV to sales | 53.13 | 50.1 | 39.7 | 36.55 | 25.62 | |
| Enterprise value over EBITDA | 106.27 | 86.78 | 70.91 | 33.52 | 51.82 | |
| EV to operating cash flow | 114.65 | 128.57 | 80.48 | 78.07 | 64.92 | |
| EV to free cash flow | 114.65 | 128.57 | 80.48 | 78.07 | 136.48 | |
| Earnings yield | 0 | 0 | 0 | 0.03 | 0 | |
| Free cash flow yield | 0.01 | 0.01 | 0.02 | 0.02 | 0.01 | |
| Debt to equity | 1.24 | 1.29 | 1.33 | 1.32 | 1.27 | |
| Debt to assets | 0.53 | 0.54 | 0.55 | 0.54 | 0.54 | |
| Net debt to EBITDA | 25.73 | 22.42 | 22.7 | 11.77 | -0.28 | |
| Current ratio | 0.37 | 0.31 | 0.3 | 0.28 | 1.37 | |
| Interest coverage | 2.18 | 2.38 | 2.33 | 2.32 | 4.53 | |
| Income quality | 7.79 | 2.71 | 3.74 | 0.68 | 11.19 | |
| Dividend Yield | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Payout ratio | 5.63 | 2.28 | 2.37 | 0.46 | 7.16 | |
| Sales general and administrative to revenue | 0.05 | 0.05 | 0.05 | 0.05 | 0.11 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | |
| Capex to operating cash flow | -0.5 | 0 | -0.2 | 0 | -0.28 | |
| Capex to revenue | -0.23 | 0 | -0.1 | 0 | -0.11 | |
| Capex to depreciation | -0.63 | 0 | -0.28 | 0 | -0.32 | |
| Stock based compensation to revenue | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | |
| Graham number | 3.81 | 5.96 | 5.77 | 13.33 | 3.41 | |
| ROIC | 0.01 | 0.01 | 0.01 | 0.01 | 0 | |
| Return on tangible assets | 0 | 0 | 0 | 0.02 | 0 | |
| Graham Net | -14.02 | -14.47 | -13.98 | -15.03 | -13.78 | |
| Working capital | -1.22B | -1.4B | -1.52B | -1.67B | 309.47M | |
| Tangible asset value | 6.63B | 6.55B | 6.49B | 6.68B | 6.87B | |
| Net current asset value | -7.4B | -7.6B | -7.71B | -7.88B | -7.33B | |
| Invested capital | 0.98 | 1.02 | 1.06 | 1.05 | 0 | |
| Average receivables | 460.13M | 464.18M | 462.58M | 449.63M | 406.39M | |
| Average payables | 239.89M | 221.37M | 212.14M | 236.82M | 132.23M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 86.52 | 83.77 | 80.16 | 75.74 | 64.32 | |
| Days payables outstanding | 102.82 | 93.41 | 87.55 | 108.08 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 1.04 | 1.07 | 1.12 | 1.19 | 1.4 | |
| Payables turnover | 0.88 | 0.96 | 1.03 | 0.83 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 0 | 0.01 | 0.01 | 0.05 | 0 | |
| Capex per share | -0.21 | 0 | -0.09 | 0 | -0.11 |
PEAK Frequently Asked Questions
What is Healthpeak Properties, Inc. stock symbol ?
Healthpeak Properties, Inc. is a US stock , located in Denver of Co and trading under the symbol PEAK
Is Healthpeak Properties, Inc. buy or a sell ?
15 stock analysts have 15 predictions with a medium analyst target price of $32.97. The lowest prediction is $26 and the highest is $40
What is PEAK stock prediction ?
With a median analyst target price of $29, 1 stock analysts have made 1 forecasts in last 90 days. $29 is the lowest and $29 is the greatest projection.
What is Healthpeak Properties, Inc. stock quote today ?
Healthpeak Properties, Inc. stock price is $21.97 today.
Is Healthpeak Properties, Inc. stock public?
Yes, Healthpeak Properties, Inc. is a publicly traded company.
Company Profile
- Volume Average 4.48M
- Market Capitalization 12.02B
- Employee 196
- CEO Mr. Scott M. Brinker
- Headquarters Denver,CO,US
- IPO Date 1985-05-23
-
Website
https://www.healthpeak.com 
Healthpeak Properties, Inc. is a fully integrated real estate investment trust (REIT) and S&P 500 company. Healthpeak owns and develops high-quality real estate in the three private-pay healthcare asset classes of Life Science, Medical Office and Senior Housing, designed to provide stability through the inevitable industry cycles. At Healthpeak, we pair our deep understanding of the healthcare real estate market with a strong vision for long-term growth.
